Status:
RECRUITING
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
Lead Sponsor:
RenJi Hospital
Conditions:
Immune System and Related Disorders
Eligibility:
All Genders
18-50 years
Brief Summary
In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new u...
Detailed Description
As an important part of the human body, the immune system is closely related to the occurrence of diseases. Based on the traditional classification methodology, it is mainly divided into two branches:...
Eligibility Criteria
Inclusion
- 1\. Age from 18 to 50 years; 2. No history of major diseases, no history of bacterial or viral infection in the past 3 months; 3. No recent history of surgery or trauma; 4 No history of smoking or alcoholism; 5. No immune system disease.
Exclusion
- 1\. Infectious diseases; 2. Tumor diseases; 3. Hematological diseases; 4. History of hypertension and diabetes; 5 Autoimmune diseases; 6 History of liver and kidney insufficiency; 7. History of previous cardiovascular diseases; 8. Pregnancy Or breast-feeding; 9. Past and current use of immunosuppressive drugs
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 3 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04871932
Start Date
February 1 2021
End Date
December 3 2026
Last Update
June 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology, Ren Ji Hospital
Shanghai, China